Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform



Developer of novel therapeutics designed to address diseases associated with or caused by, latent or persistent viral reservoirs. The company's novel therapeutics specialize in developing a novel class of nuclease-based anti-viral therapeutics to eliminate pathogenic viral genomes, enabling healthcare providers to treat their patients suffering from devastating and persistent viral infection.

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Primary Office
  • 7000 Shoreline Court
  • Suite 320
  • South San Francisco, CA 94080
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Agenovir’s full profile, request a free trial.

Agenovir Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 09-May-2018 000.00 Completed Generating Revenue
4. Early Stage VC (Series A) 17-May-2016 000.00 000.00 000.00 Completed Generating Revenue
3. Grant 01-Jan-2016 00000 Completed Generating Revenue
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Agenovir Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
% Owned
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Agenovir Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
000000000 000000 Venture Capital-Backed Tucker, GA 00 000.00 000000000 000.00
To view this company’s complete list of competitors, request access »

Agenovir Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
California Institute for Quantitative Biosciences Accelerator/Incubator 000 0000 000000 0
Celgene Corporation Minority 000 0000 000000 0
Data Collective Venture Capital Minority 000 0000 000000 0
JLABS Accelerator/Incubator 000 0000 000000 0
Lightspeed Venture Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Agenovir Executive Team (5)

Name Title Board
Dirk Thye MD Chief Executive Officer, President and Board Member
Bolyn Hubby Ph.D Chief Scientific Officer
Stephen Quake Ph.D Co-Founder, Board Member & Chairman of the Scientific Advisory Board
Angela Wu Co-Founder & Advisor

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »

Agenovir Board Members (4)

Name Representing Role Since Contact
Bruce Hironaka JD Agenovir Board Member 000 0000
Stephen Quake Ph.D Agenovir Co-Founder, Board Member & Chairman of the Scientific Advisory Board 000 0000
William Smith Agenovir Board Member, Intellectual Property 000 0000

1 Former Board Member

You’re viewing 3 of 4 board members. Get the full list »